📊 Midday Market Take
| S&P 500 | ▲ | +0.19% |
| Nasdaq | ▼ | -0.07% |
| Dow Jones | ▲ | +0.27% |
Hey there, happy to catch you mid-Wednesday as markets are doing their best impression of a group chat where nobody can agree.
The S&P 500 is nudging up 0.19% and the Dow is quietly grinding higher by 0.27%, while the Nasdaq is slipping just slightly into the red, down 0.07%. Tech is the odd one out today, dragging on the Nasdaq as some of the big growth names lose a little altitude heading into the afternoon. Keep an eye on whether buyers step in to defend those tech positions before the close, because a late-session drift lower there could shift the overall tone pretty quickly.
Arrowhead Pharmaceuticals, Inc.
|
Price
$90.37
|
Today
+21.26%
|
30 Day
+23.29%
|
90 Day
+64.23%
|
1 Year
+504.34%
|
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials.
3 Reasons to Watch ARWR
- Plozasiran Just Crushed Its Phase 3 Trials. Arrowhead reported topline results from both the SHASTA-3 and SHASTA-4 studies of Plozasiran in severe hypertriglyceridemia patients, and the drug met high expectations across the board. When your lead pipeline candidate delivers in not one but two late-stage trials on the same day, that's the kind of binary event that reshapes a stock's trajectory.
- The Stock Is Up Over 500% in One Year. ARWR has returned more than 504% over the past 12 months, and today alone it jumped over 21% on the back of the Phase 3 news. The 90-day gain of 64% tells you this isn't a one-day story either — momentum has been building for months.
- A Sector Tailwind Just Got Switched On. Drug stocks broadly caught a bid after Trump announced a zero tariff policy affecting the pharmaceutical sector, giving the whole healthcare trade an extra push. For a biotech already moving on strong clinical data, that macro tailwind is a nice bonus on top of a fundamentally driven rally.
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.
Click here to get all three AI stock names from Alexander GreenTop Market Headlines
Bank of America Says the Fed Should Raise Rates Now: 4 Dividend Inflation
Everybody across the stock and bond markets breathed a huge sigh of relief when the consumer and producer price index numbers for June were released.
Read The Full StoryNvidia poured over $7B into this (Ad)
Take a look at this… It's a radical "light-speed" device that's turning AI as we know it into "Accelerated AI", making it 100 times faster and 100 times more energy efficient. In fact, Jensen Huang, Nvidia's founder and CEO, says this device is shattering the limitations of AI and without it, AI can't scale. If you want to discover what this technology is, why Nvidia is betting billions on it… And the one stock we believe could be the biggest winner when "Accelerated AI" goes mainstream…
Click here to see all the details.
Not every market move can wait. Our text alerts deliver the ones that can't. One short alert, straight to your phone, when something is worth seeing now. No fluff. No noise. No charge.
Text Me the AlertsAre Finance Stocks Lagging Allstate (ALL) This Year?
Here is how Allstate (ALL) and Ameriprise Financial Services (AMP) have performed compared to their sector so far this year.
Read The Full StoryWhy Micron and other chip stocks are bouncing back so strongly
The recent chip sell-off presented a buying opportunity, and open-source AI models should drive more memory demand, analysts say
Read The Full StoryBUY ALERT: America's Economist Buys 10,000 Shares of $5 Stock (Ad)
The Ex-CIA economist is convinced the Trump administration is about to invest in this company.
See why he's loading up on shares here.The Mag 7 Stocks Are in a Rut—Can Strong Earnings Get Them Out of It?
The Magnificent Seven stocks may be more “Lag 7” than “Mag 7” this year, but their profits are still pretty magnificent.
Read The Full StorySmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (Ad)
A small Colorado company now owns rights to a tech that could save the entire public power grid from collapse. And billionaire Sam Altman is now an investor.
Click here to learn this company's name for free.📈 Also Trending
Jim Rickards believes the Trump administration is about to take a direct stake in a tiny $2 stock. The Trump administration has taken a direct stake in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth. Each time, shares sprinted higher.
Click here to see why Jim believes this one is next.
An innovation in gold investing is about to unleash trillions in fresh demand - giving ordinary savers the ability to move their money into gold instantly, without storage fees. When this system goes live in 2026, the ripple effects could send four specific gold stocks soaring 100X over the next dec...
Click here to discover what's coming before Wall Street wakes up
Tanker traffic through Hormuz has collapsed. LNG capacity is offline. Countries are already rationing fuel. Energy shocks don’t stay contained—they spread through the entire economy. As a market technician, I’ve studied these cycles for decades, and they always lead to monetary response—and currency...
See the four companies positioned for this shift.